CS
ORKA

Candriam SCA’s Oruka Therapeutics ORKA Stock Holding History

Candriam SCA’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.5M Sell
352,716
-58,290
-14% -$3.88M 0.15% 141
2026
Q1 		$20.2M Buy
411,006
+10,497
+3% +$365K 0.1% 196
2025
Q4 		$12.1M Buy
400,509
+33,515
+9% +$934K 0.06% 250
2025
Q3 		$7.06M Buy
366,994
+250,296
+214% +$3.71M 0.04% 318
2025
Q2 		$1.31M Hold
116,698
– – 0.01% 563
2025
Q1 		$1.2M Buy
+116,698
New +$1.46M 0.01% 565

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Candriam SCA's ORKA Position: Q2 2026 in Review

Candriam SCA reduced its Oruka Therapeutics (ORKA) stake by 14% in Q2 2026, selling an estimated $3.88M and leaving 352,716 shares worth $33.5M. The position accounts for 0.15% of the portfolio, ranked #141.

Candriam SCA first reported a position in ORKA in Q1 2025 and has held it in 6 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Candriam SCA held 352,716 shares of Oruka Therapeutics worth $33.5M as of Q2 2026.
  • Candriam SCA sold 58,290 Oruka Therapeutics shares in Q2 2026, an estimated $3.88M.
  • Oruka Therapeutics made up 0.15% of Candriam SCA's portfolio in Q2 2026, its #141 holding.
  • Candriam SCA first reported a position in Oruka Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.